Oncolys BioPharma, Jan-Mar (1Q) Net Income Loss Widens

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri May 9, 2025 3:30 pm JST Earnings

4588 Oncolys BioPharma Inc. 【J-GAAP】

Earnings Report

Oncolys BioPharma Inc. <4588> [TSE Growth] announced its financial results after the market closed on May 9th (15:30). The net loss (non-consolidated) for the first quarter of the fiscal year ending December 2025 (January to March) expanded to a loss of 811 million yen (compared to a loss of 364 million yen in the same period last year).

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Mar, 2023	35	-325	-323	-323	-18.7	ー	May 12, 2023	J-GAAP
Jan - Mar, 2024	0	-378	-363	-364	-18.2	ー	May 10, 2024	J-GAAP
Jan - Mar, 2025	0	-785	-810	-811	-32.7	ー	May 9, 2025	J-GAAP
YoY	－	-107.7%	-123.1%	-122.8%	-79.1%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2024	31	-793	-752	-754	-37.0	0	Aug 9, 2024	J-GAAP
Jan - Jun, 2025 Guidance	ー	ー	ー	ー	－	0	Feb 7, 2025	J-GAAP
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	63	-1,929	-1,913	-1,938	-108.9	0	Feb 9, 2024	J-GAAP
Dec, 2024	31	-1,681	-1,663	-1,684	-77.2	0	Feb 7, 2025	J-GAAP
Dec, 2025 Guidance	ー	ー	ー	ー	－	0	Feb 7, 2025	J-GAAP
YoY	－	－	－	－	－

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	0	-378	-363	-364	-18.2	-Inf	May 10, 2024	J-GAAP
Apr - Jun, 2024	31	-415	-389	-390	-19.1	-1,338.7	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	0	-437	-491	-492	-23.5	-Inf	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	0	-451	-420	-438	-20.1	-Inf	Feb 7, 2025	J-GAAP
Jan - Mar, 2025	0	-785	-810	-811	-32.7	-Inf	May 9, 2025	J-GAAP
YoY	－	-107.7%	-123.1%	-122.8%	-79.1%